Biosyntia Competitors and Similar CompaniesClear all

Biosyntia's competitors and similar companies include Zealand Pharma, Cyclogenix, Spexis and XL-protein.

	Biosyntia Biosyntia is a biotech company that specializes in synthetic biology and metabolic engineering.	Zealand Pharma Zealand Pharma is a biotechnology company that discovers, designs, and develops peptide-based medicines.	Cyclogenix Cyclogenix is a biotech company focused on antibody and peptide discovery.	Spexis Spexis (formerly known as Polyphor) is a bioengineering company that specializes in respiratory therapeutics.	XL-protein XL-protein is a company that develops and commercializes its proprietary PASylation technology to extend the plasma half-life of biopharmaceuticals.
Founding Date	Founding Date 2012	Founding Date 1998	Founding Date 2008	Founding Date 1996	Founding Date 2009
Type	Type Private	Type Public	Type Private	Type Public	Type Private
Tags	Tags Healthcare bioengineering biotech drug development pharma	Tags Healthcare biotech diabetes drug development	Tags Healthcare bioengineering biotech drug development pharma	Tags Healthcare bioengineering biotech drug development pharma	Tags Healthcare bioengineering biotech drug development pharma
Locations	Locations København, DK HQ	Locations Søborg, DK HQ Boston, US Marlborough, US	Locations Stevenage, GB HQ	Locations Allschwil, CH HQ	Locations Freising, DE HQ
Employees	Employees 22	Employees 385	Employees 3	Employees 50	Employees 5
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) kr9.2b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods kr816k (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit kr9.3b (FY, 2025)	Gross profit N/A	Gross profit CHF755k (FY, 2023)	Gross profit N/A
Net income	Net income N/A	Net income kr6.5b (FY, 2025)	Net income N/A	Net income (CHF19.6m) (FY, 2023)	Net income N/A